[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.30. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1987

Cyclosporine Therapy and Refractory Pneumocystis carinii PneumoniaA Potential Association

Author Affiliations

From the Departments of Medicine (Drs Franson and Lemann), Surgery (Drs Kauffman, Adams, and Cabrera), and Infection Control (Ms Hanacik), Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin, Milwaukee. Dr Franson is now with Lilly Research Laboratories, Indianapolis.

Arch Surg. 1987;122(9):1034-1035. doi:10.1001/archsurg.1987.01400210072010
Abstract

• In surveillance of 75 patients receiving renal transplants in 1984 at our Institution, five cases of Pneumocystis carinii pneumonia were detected. All five cases occurred in a subgroup of 11 patients who had received cyclosporine. A retrospective epidemiologic survey of the infected patients revealed all five were heterosexual white men with onset of Pneumocystis pneumonia two to six months after cadaveric transplantation. All received cyclosporine and corticosteroids, and four of five patients also received azathioprine; none was neutropenic or had evidence of concurrent cytomegalovirus infection. Only one of these patients responded to therapy with sulfamethoxazole and trimethoprim, one patient responded to pentamidine therapy, and the remaining three patients died. Cyclosporine use may be related to development of Pneumocystis infections that are refractory to conventional antiprotozoal therapy, and transplantation programs should closely survey patients for such complications.

(Arch Surg 1987;122:1034-1035)

×